SCHEMBL4757627

SCHEMBL4757627

O=C(O)NCc1nc(-c2ccncc2)co1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.43
TSHR P16473 1/20 0.40
ROCK1 Q13464 13/20 0.40
ROCK2 O75116 12/20 0.40
PRKACA P17612 2/20 0.38
RPS6KA5 O75582 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKCG P05129 1/20 0.38
RPS6KB1 P23443 1/20 0.38
MAPK1 P28482 1/20 0.38
AKT1 P31749 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
PRKX P51817 1/20 0.38
PRKCD Q05655 1/20 0.38
PRKG2 Q13237 1/20 0.38
DYRK1A Q13627 1/20 0.38
PRKG1 Q13976 1/20 0.38
PKN2 Q16513 1/20 0.38
CDC42BPA Q5VT25 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14289621 0.80 POLB (0.50) CES1ROCK1ROCK2PRKACARPS6KA5
SCHEMBL14313615 0.78 KMT2A (0.43) TSHRROCK1ROCK2MAPK1CASP1
SCHEMBL4758212 0.78 TSHR (0.42) TSHRROCK1ROCK2PRKACAMAP4K4
SCHEMBL12622465 0.74 CES1 (0.56) CES1CYP2C9
SCHEMBL4789041 0.73 LMNA (0.56) TSHRROCK2
SCHEMBL5122636 0.73 LOXL2 (0.41) CES1ROCK1ROCK2PRKCDPKN2
SCHEMBL4789607 0.71 GSK3B (0.41) ROCK1ROCK2PRKACARPS6KA5MAP4K4
SCHEMBL13744848 0.70 S1PR1 (0.52) CES1GSK3B
SCHEMBL5869821 0.70 NPPA (0.45) CES1GSK3B
SCHEMBL8248674 0.70 NPPA (0.45) CES1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008011557-A2 HETEROARYL INHIBITORS OF RHO KINASE BORCHARDT ALLEN J (US) 2008-01-24 WO disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE ROCK1, ROCK2, RHOA CES1 2354/4885TSHR 4034/4885ROCK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.